Healthcare News | BioTuesdays by Kilmer Lucas IR

Markets

Echelon cuts Medical Facilities PT to $5.50 from $10

Echelon Wealth Partners slashed its price target for Medical Facilities (TSX:DR) to $5.50 from $10 and maintained its “hold” rating after the company reported third quarter results that included a dramatic dividend cut...

November 8, 2019

Developments

Study finds therapeutic role for cannabis in PTSD depression

A new study in the peer-reviewed Journal of Psychopharmacology suggests that cannabis has an uplifting effect on people with post traumatic stress disorder (PTSD) and may a therapeutic role in addressing the condition...

November 8, 2019

Developments

Hepion to present on CRV431’s anti-fibrotic activity at the Liver Meeting 2019

Hepion Pharmaceuticals’ (NASDAQ:HEPA) CSO, Dr. Daren Ure, will present preclinical data on CRV431 at The Liver Meeting 2019. Dr. Ure’s presentation will address CRV431’s ability to decrease liver fibrosis in a carbon...

November 7, 2019

Developments

Vireo Health names Bruce Linton as executive chairman

Vireo Health International (CNSX:VREO; OTCQX:VREOF) appointed Bruce Linton to the role of executive chairman, where he will serve as a director, work closely with Vireo CEO and founder, Dr. Kyle Kingsley, and spearhead...

November 7, 2019

Markets

Roth sticking with Allena Pharma despite selloff

Roth Capital Partners believes Allena is getting “unnecessarily punished” on Nov. 7, despite positive URIROX-1 top-line study data, which included a high placebo response, smaller treatment effect and next steps for...

November 7, 2019

Developments

Opsens in first clinical use of OptoWire III after Health Canada approval

Opsens (TSX:OPS; OTCQX:OPSSF) announced the world’s first clinical use of its OptoWire III at the Quebec Heart and Lung Institute, following Health Canada’s recent approval of the device. OptoWire III is a...

November 7, 2019

Markets

Stifel cuts Supernus Pharma to hold; PT to $23 from $55

Stifel downgraded Supernus Pharmaceuticals (NASDAQ:SUPN) to “hold” from “buy” and slashed its price target to $23 from $55 after a Phase 3 miss with drug candidate, SPN-810, for the treatment of impulsive aggression in...

November 7, 2019

Developments

Hepion CRV431 reduces fibrosis in new model of NASH

Hepion Pharmaceuticals (NASDAQ:HEPA) reported preclinical findings where CRV431, a novel cyclophilin inhibitor, significantly decreased the extent of liver fibrosis in a Western diet (WD) animal model of NASH. The WD...

November 7, 2019

Markets

HCW ups Constellation Pharma PT to $50 from $18

H.C. Wainwright raised its price target for Constellation Pharmaceuticals (NASDAQ:CNST) to $50 from $18, saying the company’s ASH abstracts lend strong support to a bullish view on CPI-0610’s potential...

November 7, 2019

Markets

SVB Leerink cuts Amneal Pharma to MP; PT to $3 from $4

SVB Leerink downgraded Amneal Pharmaceuticals (NYSE:AMRX) to “market perform” from “outperform” and lowered its price target to $3 from $4 after the company cut its guidance. The stock closed at $2.76 on Nov. 6. Analyst...

November 7, 2019

Echelon cuts Medical Facilities PT to $5.50 from $10

Study finds therapeutic role for cannabis in PTSD depression

Hepion to present on CRV431’s anti-fibrotic activity at the Liver Meeting 2019

Vireo Health names Bruce Linton as executive chairman

Roth sticking with Allena Pharma despite selloff

Opsens in first clinical use of OptoWire III after Health Canada approval

Stifel cuts Supernus Pharma to hold; PT to $23 from $55

Hepion CRV431 reduces fibrosis in new model of NASH

HCW ups Constellation Pharma PT to $50 from $18

SVB Leerink cuts Amneal Pharma to MP; PT to $3 from $4

Follow Us

Subscribe

General

More

Subscribe